Valvular & structural heart diseaseCohort study
Long-Term Outcomes of BAV-0 Patients Compared With BAV-1 and Tricuspid Aortic Valves (TAV) Patients After Transcatheter Aortic Valve Replacement (TAVR)
- Retrospective cohort study
- international
- 3 high-volume heart centres
- Median follow-up 3.24 years (Q1-Q3: 1.25-5.00 years)
Authors' conclusion
Among patients with severe AS undergoing TAVR, BAV-0 was associated with a better long-term prognosis compared with TAV and BAV-1.
Study context
- Population
- Patients with severe AS undergoing TAVR before October 2018 at centres in China, Germany and Denmark
- Participants
- 2,553 patients
- Exposure
- BAV-0 vs BAV-1 vs TAV after TAVR
- BAV-0n = 134reference
- BAV-1n = 305
- TAVn = 2,114
- Outcome
- All-cause mortality
- Follow-up
- 5 years
Main finding
As reported in the abstract
Each group vs BAV-0Adjusted hazard ratio (95% CI)P value
BAV-1
2.38(1.32–4.28)
P = 0.004TAV
3.02(1.71–5.31)
P < 0.001Observational data: associations, not effects.
Further findings
| Outcome | Balloon-expandable | Self-expanding | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Long-term all-cause mortality in BAV, balloon-expandable vs self-expanding valves (subgroup) | 41.7% (CI 28.5%–52.5%) | 23.6% (CI 17.9%–28.8%) | 1.63 (1.05–2.51) | P = 0.028 | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Long-Term Outcomes of BAV-0 Patients Compared With BAV-1 and TAV Patients After TAVR. JACC Cardiovasc Interv. Published 23 July 2025. doi:10.1016/j.jcin.2025.05.045
Summarised from the published abstract; every number is checked against it